首页> 美国卫生研究院文献>World Journal of Gastroenterology >Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux
【2h】

Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux

机译:奥美拉唑和多潘立酮对成人哮喘合并胃食管反流的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To study the effect of combined omeprazole (Ome) and domperidone (Dom) therapy on asthma symptoms and pulmonary function in asthmatics with gastroesophageal reflux.METHODS: We selected 198 asthmatics with gastroesophageal reflux diagnosed by 24-h esophageal pH monitoring to receive Ome 20 mg twice daily and Dom 10 mg three times daily or placebo for 16 wk (1:1 double-blind randomization). Spirometry was done at baseline and after 16 wk of treatment. The primary outcome measures were: mean daily daytime and nighttime asthma symptom scores. Mean daily reflux symptom scores, albuterol use as rescue medication (number of puffs), daytime and nighttime peak expiratory flow rate (PEFR), postbronchodilator forced expiratory volume in 1 second (FEV1) and postbronchodilator forced vital capacity (FVC) were secondary outcome measures.RESULTS: Comparison of mean change from baseline between antireflux therapy and placebo groups revealed significant reduction in daytime asthma symptom score (17.4% vs 8.9%), nighttime asthma symptom score (19.6% vs 5.4%), reflux symptom score (8.7% vs 1.6%) and rescue medication use (23.2% vs 3.1%) after antireflux therapy compared to mean change in placebo group (P < 0.001). There was significant improvement in morning PEFR (7.9% vs 0.2%), evening PEFR (9.8% vs 0.5%), FEV1 (11.1% vs 3.78%) and FVC (9.3% vs 1.52%) in the antireflux therapy group compared to placebo on comparing the mean change from baseline after 16 wk (P < 0.01).CONCLUSION: Combined therapy with Ome and Dom in adult asthmatics with gastroesophageal reflux may be beneficial by reducing asthma symptoms, rescuing medication use, and improving pulmonary function.
机译:目的:研究奥美拉唑(Ome)和多潘立酮(Dom)联合治疗对胃食管反流的哮喘患者哮喘症状和肺功能的影响。方法:我们选择了198例经24小时食管pH监测诊断为胃食管反流的哮喘患者接受Ome每天两次两次20毫克,Dom每天三次10毫克或安慰剂,连续16周(1:1双盲随机分组)。在基线和治疗16周后进行肺活量测定。主要结局指标为:日间和夜间平均哮喘症状评分。平均每日反流症状评分,沙丁胺醇作为急救药物的使用(抽气次数),日间和夜间呼气峰值流速(PEFR),支气管扩张剂后1秒钟的强制呼气量(FEV1)和支气管扩张剂后的强制肺活量(FVC)是次要指标结果:比较抗反流疗法和安慰剂组的基线平均变化,发现白天哮喘症状评分(17.4%vs 8.9%),夜间哮喘症状评分(19.6%vs 5.4%),反流症状评分(8.7%vs显着降低)与安慰剂组的平均变化相比,抗反流治疗后有1.6%的人接受急救药物治疗(23.2%比3.1%)(P <0.001)。与安慰剂相比,抗反流治疗组的早晨PEFR(7.9%vs 0.2%),晚上PEFR(9.8%vs 0.5%),FEV1(11.1%vs 3.78%)和FVC(9.3%vs 1.52%)有显着改善。结论:比较Ome和Dom联合治疗成年哮喘并发胃食管反流的哮喘患者可能有益于减轻哮喘症状,抢救药物并改善肺功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号